

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

**Date of Report: 09/08/2022**

**Commission File Number: 001-39777**

**Nanobiotix S.A.**

**(Exact Name of Registrant as Specified in its Charter)**

**60 Rue de Wattignies**

**75012 Paris, France**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**EXHIBIT INDEX**

**Exhibit**      **Title**

[99.1](#)            [Press Release, dated September 8, 2022](#)

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**NANOBIOTIX S.A.**  
(Registrant)

09/08/2022

By: /s/ Bart Van Rhijn  
Bart Van Rhijn  
Chief Financial Officer

## Nanobiotix: Voting Rights and Shares Capital of the Company

*In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets  
Authority (Autorité des Marchés Financiers)*

PARIS--(BUSINESS WIRE)--September 8, 2022--Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq  
Euronext Compartment: B  
ISIN code: FR0011341205  
Nasdaq: NBTX  
Bloomberg: NANO:FP  
Reuters: NANO.PA  
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights	
		Total voting rights, theoretical (1)	Total voting rights, exercisable (2)
August 31, 2022	34,875,872	36,274,272	36,250,130

(1) The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

\*\*\*

### About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at [www.nanobiotix.com](http://www.nanobiotix.com) or follow us on LinkedIn and Twitter.

### Contacts

*Nanobiotix*

#### **Nanobiotix Communications**

Brandon Owens  
VP, Communications  
+1 (617) 852-4835  
[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

#### **Nanobiotix Investor Relations**

Kate McNeil  
SVP, Investor Relations  
+1 (609) 678-7388  
[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

*Media Relations*

#### **France – Ulysse Communication**

Pierre-Louis Germain  
+ 33 (0) 6 64 79 97 51  
[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com)

#### **LifeSci Advisors**

Ligia Vela-Reid  
+44 (0) 7413825310  
[lvela-reid@lifesciadvisors.com](mailto:lvela-reid@lifesciadvisors.com)